Focuses on developing oncology therapies targeting the DNA damage response pathway.
Cardiff Oncology, Inc. is a clinical-stage oncology company based in San Diego, California, specializing in the development of innovative treatments for cancer patients. The company's primary focus revolves around advancing therapies that target Polo-like Kinase 1 (PLK1), a key enzyme involved in cell division and cancer progression. Leading its portfolio is onvansertib, an oral selective PLK1 inhibitor designed for anti-cancer therapeutics. Cardiff Oncology's commitment extends to CY140, an inhibitor targeting PLK1, PLK2, and PLK3, currently undergoing phase 1/2 studies for both solid tumors and leukemias.
In addition to its pioneering PLK1 inhibitors, Cardiff Oncology is actively involved in clinical trials for various oncology indications. This includes metastatic colorectal cancer trials evaluating novel therapeutic approaches. Furthermore, the company's TROV-053 and TROV-054 are progressing through phase II and phase 1b/2 trials respectively, focusing on advanced stages of prostate and colorectal cancers in combination with standard treatments like Zytiga and FOLFIRI plus bevacizumab.
Originally founded as Trovagene, Inc., Cardiff Oncology, Inc. underwent a rebranding in May 2012 to reflect its dedicated mission in the oncology space. With over two decades of experience, the company collaborates closely with pharmaceutical manufacturers to advance its pipeline of innovative cancer therapies, aiming to address unmet medical needs and improve outcomes for cancer patients worldwide.